2024 Archives

Transperineal vs Transrectal Biopsy Clinical Trials: Mo’ Data Mo’ Problems

Arvin K. George, MD | Dec 2024

Arvin K. George, MD, delves into the nuances of prostate cancer biopsy techniques, focusing on the comparison between transperineal and transrectal approaches.

In this 14-minute presentation, Dr. George shares that transperineal and transrectal biopsies demonstrate equivalent cancer detection rates, particularly for clinically significant prostate cancer. However, some retrospective data suggest potential advantages of transperineal biopsy in specific anatomical areas, with notable studies emphasizing the reduced risk of infections with transperineal biopsy. Dr. George also discusses a decreased need for antibiotics and the use of local anesthesia in a transperineal approach.

Further, Dr. George reflects on the implications for clinical practice, antibiotic stewardship, and cost-effectiveness for transperineal and transrectal approaches. His talk provides a comprehensive synthesis of current evidence, encouraging a balanced and thoughtful approach to biopsy method selection.

PSMA PET for Preoperative Planning of Prostate Cancer: Nodes, Nerves and Margins

James S. Wysock, MD, MSc | Dec 2024

James Wysock, MD, MS, highlights the transformative role of novel imaging techniques, particularly PSMA PET and MRI, in improving prostate cancer diagnosis, staging, and management.

In this 14-minute presentation, Dr. Wysock explains the combination of PSMA PET and MRI significantly improves the detection of extraprostatic extension and seminal vesicle invasion compared to conventional imaging.

Meta-analyses confirm PSMA PET’s superior accuracy, particularly its high negative predictive value. This suggests that some intermediate-risk men with negative scans might safely omit extended lymph node dissection. This evidence raises important discussions about refining surgical planning and patient consent to balance risks and outcomes.

Wysock addresses emerging data supporting direct prostatectomy based on highly suspicious PSMA PET findings, bypassing biopsies. While controversial, this approach underscores the potential for imaging advancements to redefine standard workflows, especially as artificial intelligence enhances interpretation and decision-making.

Dr. Wysock emphasizes that while PSMA PET and MRI improve staging and management, these tools are still primarily validated in high-risk populations, with sensitivity challenges in lower-risk groups. The evolving role of advanced imaging, coupled with ongoing technological progress, promises to reshape prostate cancer treatment pathways.

PET Scanning in Primary Detection of Prostate Cancer

Steven P. Rowe, MD, PhD | Dec 2024

Steven P. Rowe, MD, PhD, examines the current role of PSMA PET imaging in prostate cancer detection and management, emphasizing its strengths, limitations, and areas requiring further research.

Dr. Rowe asserts in this detailed 15-minute talk that PSMA PET excels in identifying metastatic sites and aiding metastasis-directed therapy. He references advanced trials, such as OSPREY and Lighthouse, revealing its utility’s nuances.

Much of the discussion underscores the need for caution in interpreting data on extra-prostatic extension, with Rowe questioning recent claims of PSMA PET’s superiority over MRI. Challenges in standardizing interpretation across different scoring systems, such as PIRADS and Primary Score, are addressed, suggesting the potential oversimplification of tumor categorization. The talk also introduces technological barriers inherent in PET imaging.

Practical insights are provided into PSMA PET’s use in clinical settings. The societal and financial implications of widespread PSMA PET adoption are highlighted, stressing the need for cost-effective implementation strategies.

Utility of Micro-Ultrasound in Prostate Cancer Active Surveillance

Stefano Fanti, MD | Dec 2024

Stefano Fanti, MD, provides an expert overview of molecular imaging in prostate cancer, focusing on the transformative role of PSMA PET.

Pediatric to Adult Transition in Urology

Daniel Wood, PhD, MBBS, FRCS | Dec 2024

Daniel Wood, MBBS, PhD, FRCS, provides an overview of the transition from pediatric to adult care for patients with complex urological conditions. This 6-minute talk highlights the challenges patients face as they move from a trusted pediatric care team to adult providers, emphasizing the need for continuity of care. Dr. Wood explains that transition is not merely the transfer of care but involves preparing young adults to manage their health, develop long-term care plans, and ensure they are connected with adult healthcare providers.

Wood touches on the significance of managing neuropathic bladder conditions in patients transitioning from pediatric to adult care. He underscores the necessity of addressing sexual health and fertility, topics often overlooked. The speaker also stresses the role of multidisciplinary care, involving nephrologists and urologists, to optimize patient outcomes.